Report Thumbnail
Product Code QY0914712486X65
Published Date 2024/4/22
QY Research
English95 PagesGlobal

Cancer Drug based on PARP Inhibitor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code QY0914712486X65◆The Apr 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/4/22
QY Research
English 95 PagesGlobal

Cancer Drug based on PARP Inhibitor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP)
The global market for Cancer Drug based on PARP Inhibitor was estimated to be worth US$ 5904.1 million in 2023 and is forecast to a readjusted size of US$ 13040 million by 2030 with a CAGR of 8.9% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Drug based on PARP Inhibitor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cancer Drug based on PARP Inhibitor by region & country, by Type, and by Application.
The Cancer Drug based on PARP Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug based on PARP Inhibitor.
Market Segmentation
By Company
AstraZeneca
Merck & Co
GSK
Clovis Oncology
Pfizer
Zai Lab
Segment by Type:
Lynparza
Zejula
Rubraca
Talzenna
Segment by Application
Ovarian Cancer
Breast Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Drug based on PARP Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cancer Drug based on PARP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cancer Drug based on PARP Inhibitor in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

  • 1 Market Overview

    • 1.1 Cancer Drug based on PARP Inhibitor Product Introduction
    • 1.2 Global Cancer Drug based on PARP Inhibitor Market Size Forecast
      • 1.2.1 Global Cancer Drug based on PARP Inhibitor Sales Value (2019-2030)
      • 1.2.2 Global Cancer Drug based on PARP Inhibitor Sales Volume (2019-2030)
      • 1.2.3 Global Cancer Drug based on PARP Inhibitor Sales Price (2019-2030)
    • 1.3 Cancer Drug based on PARP Inhibitor Market Trends & Drivers
      • 1.3.1 Cancer Drug based on PARP Inhibitor Industry Trends
      • 1.3.2 Cancer Drug based on PARP Inhibitor Market Drivers & Opportunity
      • 1.3.3 Cancer Drug based on PARP Inhibitor Market Challenges
      • 1.3.4 Cancer Drug based on PARP Inhibitor Market Restraints
    • 1.4 Assumptions and Limitations
    • 1.5 Study Objectives
    • 1.6 Years Considered

  • 2 Competitive Analysis by Company

    • 2.1 Global Cancer Drug based on PARP Inhibitor Players Revenue Ranking (2023)
    • 2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Company (2019-2024)
    • 2.3 Global Cancer Drug based on PARP Inhibitor Players Sales Volume Ranking (2023)
    • 2.4 Global Cancer Drug based on PARP Inhibitor Sales Volume by Company Players (2019-2024)
    • 2.5 Global Cancer Drug based on PARP Inhibitor Average Price by Company (2019-2024)
    • 2.6 Key Manufacturers Cancer Drug based on PARP Inhibitor Manufacturing Base Distribution and Headquarters
    • 2.7 Key Manufacturers Cancer Drug based on PARP Inhibitor Product Offered
    • 2.8 Key Manufacturers Time to Begin Mass Production of Cancer Drug based on PARP Inhibitor
    • 2.9 Cancer Drug based on PARP Inhibitor Market Competitive Analysis
      • 2.9.1 Cancer Drug based on PARP Inhibitor Market Concentration Rate (2019-2024)
      • 2.9.2 Global 5 and 10 Largest Manufacturers by Cancer Drug based on PARP Inhibitor Revenue in 2023
      • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug based on PARP Inhibitor as of 2023)
    • 2.10 Mergers & Acquisitions, Expansion

  • 3 Segmentation by Type

    • 3.1 Introduction by Type
      • 3.1.1 Lynparza
      • 3.1.2 Zejula
      • 3.1.3 Rubraca
      • 3.1.4 Talzenna
    • 3.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Type
      • 3.2.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Type (2019 VS 2023 VS 2030)
      • 3.2.2 Global Cancer Drug based on PARP Inhibitor Sales Value, by Type (2019-2030)
      • 3.2.3 Global Cancer Drug based on PARP Inhibitor Sales Value, by Type (%) (2019-2030)
    • 3.3 Global Cancer Drug based on PARP Inhibitor Sales Volume by Type
      • 3.3.1 Global Cancer Drug based on PARP Inhibitor Sales Volume by Type (2019 VS 2023 VS 2030)
      • 3.3.2 Global Cancer Drug based on PARP Inhibitor Sales Volume, by Type (2019-2030)
      • 3.3.3 Global Cancer Drug based on PARP Inhibitor Sales Volume, by Type (%) (2019-2030)
    • 3.4 Global Cancer Drug based on PARP Inhibitor Average Price by Type (2019-2030)

  • 4 Segmentation by Application

    • 4.1 Introduction by Application
      • 4.1.1 Ovarian Cancer
      • 4.1.2 Breast Cancer
      • 4.1.3 Other
    • 4.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Application
      • 4.2.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Application (2019 VS 2023 VS 2030)
      • 4.2.2 Global Cancer Drug based on PARP Inhibitor Sales Value, by Application (2019-2030)
      • 4.2.3 Global Cancer Drug based on PARP Inhibitor Sales Value, by Application (%) (2019-2030)
    • 4.3 Global Cancer Drug based on PARP Inhibitor Sales Volume by Application
      • 4.3.1 Global Cancer Drug based on PARP Inhibitor Sales Volume by Application (2019 VS 2023 VS 2030)
      • 4.3.2 Global Cancer Drug based on PARP Inhibitor Sales Volume, by Application (2019-2030)
      • 4.3.3 Global Cancer Drug based on PARP Inhibitor Sales Volume, by Application (%) (2019-2030)
    • 4.4 Global Cancer Drug based on PARP Inhibitor Average Price by Application (2019-2030)

  • 5 Segmentation by Region

    • 5.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Region
      • 5.1.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Region: 2019 VS 2023 VS 2030
      • 5.1.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Region (2019-2024)
      • 5.1.3 Global Cancer Drug based on PARP Inhibitor Sales Value by Region (2025-2030)
      • 5.1.4 Global Cancer Drug based on PARP Inhibitor Sales Value by Region (%), (2019-2030)
    • 5.2 Global Cancer Drug based on PARP Inhibitor Sales Volume by Region
      • 5.2.1 Global Cancer Drug based on PARP Inhibitor Sales Volume by Region: 2019 VS 2023 VS 2030
      • 5.2.2 Global Cancer Drug based on PARP Inhibitor Sales Volume by Region (2019-2024)
      • 5.2.3 Global Cancer Drug based on PARP Inhibitor Sales Volume by Region (2025-2030)
      • 5.2.4 Global Cancer Drug based on PARP Inhibitor Sales Volume by Region (%), (2019-2030)
    • 5.3 Global Cancer Drug based on PARP Inhibitor Average Price by Region (2019-2030)
    • 5.4 North America
      • 5.4.1 North America Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 5.4.2 North America Cancer Drug based on PARP Inhibitor Sales Value by Country (%), 2023 VS 2030
    • 5.5 Europe
      • 5.5.1 Europe Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 5.5.2 Europe Cancer Drug based on PARP Inhibitor Sales Value by Country (%), 2023 VS 2030
    • 5.6 Asia Pacific
      • 5.6.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 5.6.2 Asia Pacific Cancer Drug based on PARP Inhibitor Sales Value by Country (%), 2023 VS 2030
    • 5.7 South America
      • 5.7.1 South America Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 5.7.2 South America Cancer Drug based on PARP Inhibitor Sales Value by Country (%), 2023 VS 2030
    • 5.8 Middle East & Africa
      • 5.8.1 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 5.8.2 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Value by Country (%), 2023 VS 2030

  • 6 Segmentation by Key Countries/Regions

    • 6.1 Key Countries/Regions Cancer Drug based on PARP Inhibitor Sales Value Growth Trends, 2019 VS 2023 VS 2030
    • 6.2 Key Countries/Regions Cancer Drug based on PARP Inhibitor Sales Value
      • 6.2.1 Key Countries/Regions Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.2.2 Key Countries/Regions Cancer Drug based on PARP Inhibitor Sales Volume, 2019-2030
    • 6.3 United States
      • 6.3.1 United States Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.3.2 United States Cancer Drug based on PARP Inhibitor Sales Value by Type (%), 2023 VS 2030
      • 6.3.3 United States Cancer Drug based on PARP Inhibitor Sales Value by Application, 2023 VS 2030
    • 6.4 Europe
      • 6.4.1 Europe Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.4.2 Europe Cancer Drug based on PARP Inhibitor Sales Value by Type (%), 2023 VS 2030
      • 6.4.3 Europe Cancer Drug based on PARP Inhibitor Sales Value by Application, 2023 VS 2030
    • 6.5 China
      • 6.5.1 China Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.5.2 China Cancer Drug based on PARP Inhibitor Sales Value by Type (%), 2023 VS 2030
      • 6.5.3 China Cancer Drug based on PARP Inhibitor Sales Value by Application, 2023 VS 2030
    • 6.6 Japan
      • 6.6.1 Japan Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.6.2 Japan Cancer Drug based on PARP Inhibitor Sales Value by Type (%), 2023 VS 2030
      • 6.6.3 Japan Cancer Drug based on PARP Inhibitor Sales Value by Application, 2023 VS 2030
    • 6.7 South Korea
      • 6.7.1 South Korea Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.7.2 South Korea Cancer Drug based on PARP Inhibitor Sales Value by Type (%), 2023 VS 2030
      • 6.7.3 South Korea Cancer Drug based on PARP Inhibitor Sales Value by Application, 2023 VS 2030
    • 6.8 Southeast Asia
      • 6.8.1 Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.8.2 Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value by Type (%), 2023 VS 2030
      • 6.8.3 Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value by Application, 2023 VS 2030
    • 6.9 India
      • 6.9.1 India Cancer Drug based on PARP Inhibitor Sales Value, 2019-2030
      • 6.9.2 India Cancer Drug based on PARP Inhibitor Sales Value by Type (%), 2023 VS 2030
      • 6.9.3 India Cancer Drug based on PARP Inhibitor Sales Value by Application, 2023 VS 2030

  • 7 Company Profiles

    • 7.1 AstraZeneca
      • 7.1.1 AstraZeneca Company Information
      • 7.1.2 AstraZeneca Introduction and Business Overview
      • 7.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2019-2024)
      • 7.1.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Offerings
      • 7.1.5 AstraZeneca Recent Development
    • 7.2 Merck & Co
      • 7.2.1 Merck & Co Company Information
      • 7.2.2 Merck & Co Introduction and Business Overview
      • 7.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2019-2024)
      • 7.2.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Offerings
      • 7.2.5 Merck & Co Recent Development
    • 7.3 GSK
      • 7.3.1 GSK Company Information
      • 7.3.2 GSK Introduction and Business Overview
      • 7.3.3 GSK Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2019-2024)
      • 7.3.4 GSK Cancer Drug based on PARP Inhibitor Product Offerings
      • 7.3.5 GSK Recent Development
    • 7.4 Clovis Oncology
      • 7.4.1 Clovis Oncology Company Information
      • 7.4.2 Clovis Oncology Introduction and Business Overview
      • 7.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2019-2024)
      • 7.4.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Offerings
      • 7.4.5 Clovis Oncology Recent Development
    • 7.5 Pfizer
      • 7.5.1 Pfizer Company Information
      • 7.5.2 Pfizer Introduction and Business Overview
      • 7.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2019-2024)
      • 7.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Offerings
      • 7.5.5 Pfizer Recent Development
    • 7.6 Zai Lab
      • 7.6.1 Zai Lab Company Information
      • 7.6.2 Zai Lab Introduction and Business Overview
      • 7.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2019-2024)
      • 7.6.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Offerings
      • 7.6.5 Zai Lab Recent Development

  • 8 Industry Chain Analysis

    • 8.1 Cancer Drug based on PARP Inhibitor Industrial Chain
    • 8.2 Cancer Drug based on PARP Inhibitor Upstream Analysis
      • 8.2.1 Key Raw Materials
      • 8.2.2 Raw Materials Key Suppliers
      • 8.2.3 Manufacturing Cost Structure
    • 8.3 Midstream Analysis
    • 8.4 Downstream Analysis (Customers Analysis)
    • 8.5 Sales Model and Sales Channels
      • 8.5.1 Cancer Drug based on PARP Inhibitor Sales Model
      • 8.5.2 Sales Channel
      • 8.5.3 Cancer Drug based on PARP Inhibitor Distributors

  • 9 Research Findings and Conclusion

  • 10 Appendix

    • 10.1 Research Methodology
      • 10.1.1 Methodology/Research Approach
      • 10.1.2 Data Source
    • 10.2 Author Details
    • 10.3 Disclaimer
USD 3,950 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.